Document is current
Any future updates will be listed below
-
Authors
Martinez, Jose
Palma, Jose-Alberto
Norcliffe-Kaufmann, Lucy
Garakani, Amir
Kaufmann, Horacio
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (U54NS065736)
Dysautonomia Foundation
- License Information
-
More Information
Article History
Received: 21 January 2020
Accepted: 13 March 2020
First Online: 3 April 2020
Compliance with ethical standards
:
: J.M.: Consulting fees from Theravance Biopharma. Funding from the NIH, Michael J. Fox Foundation, MSA Coalition, Familial Dysautonomia Foundation, and FDA. J.A.P.: Funding from the NIH, Michael J. Fox Foundation, MSA Coalition, Familial Dysautonomia Foundation, and FDA. He is an advisory Board Member for Lundbeck, Biogen; he is the managing editor of <i>Clinical Autonomic Research</i>. L.N.K.: Consulting fees from Theravance Biopharma. Funding from the NIH, Michael J. Fox Foundation, MSA Coalition, Familial Dysautonomia Foundation, and FDA. A.G.: No conflict of interests. H.K.: Funding from the NIH, Michael J. Fox Foundation, MSA Coalition, Familial Dysautonomia Foundation, and FDA. Advisory Board Member for Lunbeck, Biogen, Theravance, Biohaven, Eli Lilly, Pfizer, and AstraZeneca; Editor-in-Chief of <i>Clinical Autonomic Research</i>.
